Kintara Therapeutics Stock Target Price
| KTRADelisted Stock | USD 6.30 0.14 2.17% |
Kintara Therapeutics fundamentals help investors to digest information that contributes to Kintara Therapeutics' financial success or failures. It also enables traders to predict the movement of Kintara Stock. The fundamental analysis module provides a way to measure Kintara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kintara Therapeutics stock.
Kintara |
Kintara Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kintara Therapeutics' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kintara Therapeutics could also be used in its relative valuation, which is a method of valuing Kintara Therapeutics by comparing valuation metrics of similar companies.Kintara Therapeutics is currently under evaluation in target price category among its peers.
Kintara Fundamentals
| Return On Equity | -3.71 | |||
| Return On Asset | -1.04 | |||
| Current Valuation | 17.98 M | |||
| Shares Outstanding | 55.66 M | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 1.47 % | |||
| Number Of Shares Shorted | 5.43 M | |||
| Price To Book | 7.81 X | |||
| EBITDA | (8.5 M) | |||
| Net Income | (8.32 M) | |||
| Cash And Equivalents | 11.78 M | |||
| Cash Per Share | 0.15 X | |||
| Total Debt | 2.44 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 3.32 X | |||
| Book Value Per Share | (0.12) X | |||
| Cash Flow From Operations | (7.18 M) | |||
| Short Ratio | 1.14 X | |||
| Earnings Per Share | (11.20) X | |||
| Target Price | 14.0 | |||
| Beta | 0.81 | |||
| Market Capitalization | 11.99 M | |||
| Total Asset | 6.2 M | |||
| Retained Earnings | (159.88 M) | |||
| Working Capital | 188 K | |||
| Net Asset | 6.2 M |
About Kintara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kintara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kintara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kintara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |